Prevention of Acute Radiation Enteritis With Glutamine

This study has been completed.
Information provided by:
Castilla-León Health Service Identifier:
First received: January 22, 2009
Last updated: May 24, 2011
Last verified: January 2009

Ionizing radiation has cytotoxic effects, and is commonly used as treatment for neoplasm. A common adverse effect of radiation is acute diarrhoea. Glutamine is an aminoacid with antioxidant effects that can protect tissues of damage dued to radiation. The investigators designed a randomized, double-blind trial phase III to study if glutamine prevents acute radiation enteritis.

Condition Intervention Phase
Acute Radiation Enteritis
Dietary Supplement: Glutamine
Dietary Supplement: Whole protein
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Efficacy of Glutamine in the Prevention of Acute Radiation Enteritis Among Patients Treated With Radiation of Abdomen and Pelvis.

Resource links provided by NLM:

Further study details as provided by Castilla-León Health Service:

Primary Outcome Measures:
  • Number of patients with acute radiation enteritis [ Time Frame: 2 months ] [ Designated as safety issue: No ]
    RTOG criteria

Secondary Outcome Measures:
  • Reduction in inflammatory markers and oxydative stress [ Time Frame: 2 months ] [ Designated as safety issue: No ]

Enrollment: 70
Study Start Date: January 2009
Study Completion Date: May 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Glutamine Dietary Supplement: Glutamine
Oral glutamine 30g/day
Placebo Comparator: Whole protein Dietary Supplement: Whole protein
Oral whole protein 30 g/day


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 18 yr
  • Gynaecological,prostatic, rectal or other abdominal cancer
  • Radiotherapy with/without chemotherapy

Exclusion Criteria:

  • life expectancy < 1 yr
  • Age < 18 yr
  • gut diseases: inflammatory bowel disease,sprue, irritable bowel disease...
  • moderate to severe chronic renal failure
  • hepatic cirrhosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00828399

Complejo Asistencial de León.
Leon, Spain, 24008
Sponsors and Collaborators
Castilla-León Health Service
Principal Investigator: Alfonso Vidal Casariego, MD Sección de Endocrinología y Nutrición. Complejo Asistencial de León
  More Information

Responsible Party: MD Alfonso Vidal Casariego, Complejo Asistencial de Leóm Identifier: NCT00828399     History of Changes
Other Study ID Numbers: 001-2008-BecaSacyl
Study First Received: January 22, 2009
Last Updated: May 24, 2011
Health Authority: Spain: Ethics Committee

Keywords provided by Castilla-León Health Service:
Oxydative stress

Additional relevant MeSH terms:
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases processed this record on October 08, 2015